news

Uncertainty derails $2.5 trillion in global construction activity projected for 2025

Currie & Brown launches Construction Certainty Index to help organisations navigate rising volatility LONDON, Sept. 30, 2025 /PRNewswire/ -- $2.5…

3 months ago

DAR GLOBAL PLANS TO LAUNCH TRUMP PLAZA JEDDAH IN SECOND COLLABORATION WITH THE TRUMP ORGANIZATION, FOLLOWING THE SUCCESS OF TRUMP TOWER JEDDAH

JEDDAH, Saudi Arabia, Sept. 29, 2025 /PRNewswire/ -- Dar Global (LSE: DAR), the London-listed international luxury real estate developer, has…

3 months ago

BitMine Immersion (BMNR) Announces ETH Holdings Exceeding 2.65 Million Tokens and Total Crypto and Cash Holdings of $11.6 Billion

BitMine now owns greater than 2% of the ETH token supply as it moves towards the 'Alchemy of 5%' BitMine…

3 months ago

UnionPay International Drives Global Interoperability via China’s Cross-border Interconnection Payment Gateway

SHANGHAI, Sept. 29, 2025 /PRNewswire/ -- On September 16, it was announced that China's Cross-border Interconnection Gateway (CPG) had officially…

3 months ago

Beko scales Second-Life ‘Reduce-Refurbish-Recycle’ program to factory level across Europe

-  Beko extends product lifecycles, proving that circularity delivers both affordability and sustainability. -  In 2024, more than 114,000 appliances…

3 months ago

Kenstar Brings Comfort, Style, and Savings to Festive Celebrations

Unveils India's first 5-Star BEE-rated air coolers, next-gen water heaters, and kitchen appliances GURUGRAM, India, Sept. 29, 2025 /PRNewswire/ -- As…

3 months ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

September 29, 2025 19:30 ET  | Source: Nxera Pharma Tokyo, Japan and Cambridge and London, UK, 30 September 2025 –…

3 months ago

Artelo Biosciences Announces Proposed Underwritten Public Offering

September 29, 2025 19:15 ET  | Source: Artelo Biosciences SOLANA BEACH, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences,…

3 months ago

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Nave or Resistant R/M-HNSCC

Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163% (26/41)…

3 months ago

Viva Biotech Receives Frost & Sullivan’s 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry

Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation…

3 months ago